InMed Pharmaceuticals Reports Net Sales Of $575K For 6 Months Since BayMedica Acquisition
InMed Pharmaceuticals Inc. (NASDAQ:INM), a leader in research, development, manufacturing and commercialization of rare cannabinoids, released unaudited financial results for the third quarter of the fiscal year 2022 which ended March 31, 2022.